Bortezomib and lenalidomide as first-line treatment for older patients with myeloma

Peter Barth, MD, of Brown University, Providence, RI, discusses the benefit found in triplet induction therapy compared to that of various double induction therapies in elderly multiple myeloma patients in a retrospective study. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.